NovartisNovartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 102,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit

Novartis RSS Channel

Title Filter      Display #  
# Article Title
1 Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
2 Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria
3 Novartis extends leadership in clinical trial data transparency
4 Novartis expands cancer immunotherapy research program with acquisition of CoStim
5 Novartis recognized among world's most sustainable companies in Corporate Knights Global 100
6 Novartis Africa Day highlights company's efforts to expand access to healthcare
7 Novartis Foundation launches new leprosy strategy at symposium on disease elimination
8 Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
9 Novartis announces positive clinical trial results for novel H7N9 vaccine
10 Novartis delivers strong sales performance in third quarter
11 Novartis launches fully interactive Facebook ‘Retina App’ on World Sight Day to raise awareness of retinal disease
12 Secukinumab (AIN457) showed superiority over Enbrel®
13 Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths
14 Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
15 Novartis announces an exclusive global licensing and research collaboration with Regenerex
16 Novartis holds annual healthcare entrepreneur competition
17 Novartis first company accredited with global CEO Cancer Gold Standard
18 Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
19 Novartis delivered growth across all divisions in second quarter
20 Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]